COMPARATIVE STUDY
JOURNAL ARTICLE
MULTICENTER STUDY

Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study

Philippe Bernard, Ziad Reguiai, Emmanuelle Tancrède-Bohin, Nadege Cordel, Patrice Plantin, Christine Pauwels, Loïc Vaillant, Florent Grange, Marie-Aleth Richard-Lallemand, Bruno Sassolas, Jean-Claude Roujeau, Catherine Lok, Catherine Picard-Dahan, Olivier Chosidow, Fabien Vitry, Pascal Joly
Archives of Dermatology 2009, 145 (5): 537-42
19451497

OBJECTIVE: To identify prognostic factors for relapse in the first year after cessation of therapy in bullous pemphigoid (BP).

DESIGN: Prospective, multicenter, cohort study (January 1, 2000, through December 31, 2006).

SETTING: Fifteen French dermatology departments. Patients Patients with BP in remission under low doses of topical or systemic corticosteroids. Interventions Cessation of corticosteroid treatment (day 0) followed by a systematic clinical and immunologic follow-up.

MAIN OUTCOME MEASURES: The end point was clinical relapse within the first year after cessation of therapy. Associations of clinical, biological, and immunologic (including direct immunofluorescence, serum anti-basement membrane zone autoantibodies, and serum BP180 autoantibodies by enzyme-linked immunosorbent assay [ELISA] on day 0) variables with clinical relapse were assessed by means of univariate and multivariate analyses.

RESULTS: On day 0, 30 of 114 patients (26.3%) still had a positive result of direct immunofluorescence, 63 of 112 (56.3%) had circulating anti-basement membrane zone autoantibodies, and 34 of 57 (60%) had anti-BP180 antibodies by ELISA. At month 12, 22 patients were dead (n = 11) or lost to follow-up (n = 11), 51 were in remission, and 45 had had relapses (mean interval to relapse, 3.2 months). Factors predictive of relapse within 12 months after cessation of therapy were a positive result of direct immunofluorescence microscopy (P = .02), a greater age (P = .01), and high-titer ELISA scores (P = .02) on day 0. In multivariate analysis, the only factor independently predictive of relapse was a high-titer ELISA score on day 0 (odds ratio, 11.00; 95% confidence interval, 1.29-93.76).

CONCLUSIONS: High-titer anti-BP180 ELISA score and, to a lesser degree, a positive direct immunofluorescence finding are good indicators of further relapse of BP. At least 1 of these tests should be performed before therapy is discontinued.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
19451497
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"